New IMBRUVICA® (ibrutinib) Data in Fixed-Duration Combi

/PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new and updated results from the Phase 2 CAPTIVATE study evaluating...

Related Keywords

Spain , Vienna , Wien , Austria , Barcelona , Comunidad Autonoma De Cataluna , Sant Pau , Carol Moreno , Christie Corbett , None Of The Janssen Pharmaceutical Companies , Abbvie Company , Janssen Biotech Inc , European Hematology Association Annual Congress , European Hematology Association , Drug Administration , Janssen Research Development , Janssen Pharmaceutical Companies , Janssen Pharmaceutical Companies Of Johnson , Exchange Commission , Autonomous University Of Barcelona , Companies Of Johnson , Johnson , National Comprehensive Cancer Network , Hematology Association , Annual Congress , Consultant Hematologist , Autonomous University , Janssen Biotech , Year Follow Up Data , Based Combination Regimen , Previously Untreated Patients , Confidence Interval , Guided Cohort , Thenew England Journal , Medicine Evidence , National Comprehensive Cancer , Cardiac Failure , Sudden Death , Primary Malignancies , Lysis Syndrome , Fetal Toxicity , Pharmaceutical Companies , Infectious Diseases , Private Securities Litigation Reform Act , Janssen Research , Annual Report , Note Regarding Forward Looking , Quarterly Reports , Duration Ibrutinib , First Line Treatment , Chronic Lymphocytic , Small Lymphocytic Lymphoma , Year Follow Up From , Hematology Association Annual , Translational Analyses , Duration Ibrutinib Venetoclax , Chronic Lymphocytic Leukemia , Clinical Practice Guidelines , Comprehensive Cancer , Accessed June , Janssen Oncology ,